Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Category: Uncategorized

Tranylcypromine

Plain-language summaryIntrigue 65 / 100

Tranylcypromine (Parnate) is a first-generation MAOI from 1961 with a chemical backbone closely related to amphetamine. That structural quirk gives it a small but real direct stimulant component on top of the MAO inhibition, producing faster onset (1 to 2 weeks rather than the 4 to 6 weeks typical of MAOIs) and a more activating subjective profile than phenelzine. It carries the same dietary tyramine restrictions and drug interaction risks as the rest of its class. Like phenelzine it earns its place in the modern psychiatric armamentarium specifically for treatment-resistant depression cases where everything else has failed. The recent Tranylcypromine in Treatment-Resistant Depression literature has revived interest in disciplined modern use of these older drugs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

41/100

Decades-old irreversible MAOI with real clinical history but negligible frontier research appeal

Look, tranylcypromine is a compound researchers already know. FDA-approved in 1961 under Parnate, it was the first non-hydrazine MAOI and carries a structurally unusual cyclopropylamine scaffold that bears a family resemblance to amphetamine. That amphetamine relationship is actually what makes it marginally more interesting than phenelzine on paper: in addition to irreversible MAO-A and MAO-B inhibition, it produces weak monoamine release, which probably explains the faster clinical onset (1 to 2 weeks versus 3 to 6 for phenelzine) and the mildly activating subjective profile investigators and clinicians have described for decades.

The mechanism, though, isnt novel. Irreversible non-selective MAO inhibition is 60-year-old pharmacology. The tyramine cheese effect is a textbook drug interaction. Plasma half-life is short (1.5 to 3.2 hours) but enzyme recovery is slow (5 to 10 days), which creates the dietary and drug-interaction burden that has made this class clinically awkward and commercially marginal since SSRIs came along. For a bench scientist, that interaction profile isnt interesting, its inconvenient background noise.

Where it retains real, if modest, value is as a reference compound. If your program is probing MAO biology, monoamine release, or you need a positive control in a dopaminergic assay, tranylcypromine is a well-characterized tool with known selectivity and a deep pharmacokinetic record. The (-)-trans isomer is the pharmacologically dominant form; the clinical preparation is racemic, which opens a stereochemistry question that’s occasionally been worth pursuing. And the cyclopropylamine scaffold itself has inspired structural analogs in newer programs, so investigators doing scaffold-level work sometimes keep it on the bench as a structural reference.

We dont think it belongs at the center of a serious research program right now. Treatment-resistant depression is genuinely interesting territory, and MAOIs are experiencing mild clinical rehabilitation in TRD discussions, but that reappraisal largely benefits phenelzine data and the class generally rather than generating new mechanistic questions specific to tranylcypromine. The frontier in TRD has moved toward ketamine, psychoplastogens, and the early GLP-1/neuroinflammation angle. If youre studying MAO biology specifically, selegiline gives you selective MAO-B inhibition for a cleaner dissection. If youre studying irreversible MAO-A, phenelzine has deeper clinical literature.

Tranylcypromine is a mature, approved drug with decades of human data. That means the evidence quality is better than most compounds in this library, and the translational signal is real. But research-merit scoring isnt about knowing a compound works. It’s about whether theres something left to discover. Here, the well is mostly dry.

Novelty

18

Mechanism promise

32

In-category differentiation

38

Evidence quality

60

Translational signal

58

Research bench value

55

Rationale Tranylcypromine scores low on novelty and mechanism because non-selective irreversible MAO inhibition is thoroughly mapped 1960s pharmacology, and the amphetamine-like dual mechanism is a curiosity rather than a research catalyst. Its bench value as a non-hydrazine MAOI reference compound and positive control in monoamine release assays keeps the overall from falling below the low forties, but theres no active frontier here.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Irreversible non-selective MAO inhibitor (amphetamine-related)

A non-hydrazine cyclopropylamine MAOI structurally related to amphetamine; rapid-onset compared to phenelzine.

Abstract

Tranylcypromine ((1S,2R)-2-phenylcyclopropan-1-amine; CAS 155-09-9; molecular formula C9H11N; molecular weight 133.19) is a non-hydrazine cyclopropylamine MAOI approved by the FDA in 1961 under the trade name Parnate. The cyclopropylamine scaffold is structurally related to amphetamine, producing weak monoamine release in addition to MAO inhibition; the result is faster antidepressant onset (1 to 2 weeks) than phenelzine (3 to 6 weeks) and a mildly activating subjective profile. Inhibition of both MAO-A and MAO-B is irreversible, with similar tyramine cheese-effect risk. Plasma half-life is 1.5 to 3.2 hours, but enzyme inhibition persists for 5 to 10 days. The (-)-trans isomer is the predominant active form; clinical preparations are racemic. Hepatic metabolism is minor; the compound is largely excreted unchanged. Approved for major depressive disorder; used in atypical and treatment-resistant depression. Used as a non-hydrazine MAOI reference compound and as a positive control in dopaminergic and norepinephrine release studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-227Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Lamotrigine

Plain-language summaryIntrigue 72 / 100

Lamotrigine (Lamictal) is a clean voltage-gated sodium channel blocker from GSK, approved by the FDA in 1994 for partial seizures and now equally important as a first-line mood stabilizer for bipolar depression and bipolar maintenance. It is unusual in mood medicine because, unlike lithium and valproate, it is more effective at preventing depressive episodes than manic ones. The mechanism is state-dependent: it preferentially binds inactivated sodium channels, which selectively dampens hyperactive neurons while leaving normal firing alone. The infamous risk is Stevens-Johnson syndrome (potentially fatal skin reaction) if titrated too quickly, which is why the dose-up schedule is conservative and stretched over weeks. Otherwise it is one of the most metabolically clean drugs in psychiatry. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

52/100

Mature VGSC blocker with uniquely differentiated bipolar depression profile and real but aging bench utility

Here’s the thing about lamotrigine: it’s one of the more mechanistically interesting anticonvulsants on paper, but it’s been around since 1994, and that age dominates the novelty picture. The core mechanism, state-dependent inhibition of voltage-gated sodium channels with preferential binding to the inactivated state, is thoroughly mapped. The downstream story, reduced presynaptic release of glutamate and aspartate, is well-understood. Secondary high-voltage-activated calcium channel inhibition and weak 5-HT3 antagonism add texture to the profile, but none of that is new territory for anyone working in this space.

What we actually find interesting about lamotrigine in a research context is the bipolar depression dissociation. Most mood stabilizers, lithium being the reference, are clearly better at suppressing mania than preventing depressive episodes. Lamotrigine inverts that relationship: the Calabrese et al. phase 3 maintenance datasets and the GSK registration trials established repeatedly that it’s primarily effective on the depressive pole. That asymmetry is real, replicated, and the mechanistic explanation for it remains genuinely open. If you’re studying the neuropharmacology of depression versus mania at the circuit or sodium channel isoform level, that gap is where the bench value lives.

As a pharmacological probe, lamotrigine is one of the cleaner VGSC tools available. Glucuronidation-dominated metabolism means fewer CYP2 interactions than carbamazepine or phenytoin, making it more tractable in multi-compound studies. For investigators working on glutamatergic excitability, firing-frequency-dependent channel pharmacology, or sodium channel isoform selectivity questions, its probe value is legitimate. It’s not indispensable in the way rapamycin is to mTOR work, but its clean metabolic profile and well-characterized kinetics make it useful in the right experimental context.

The honest constraint here is that theres not much frontier left. The mechanism is characterized to the point where a new bench scientist will find more questions answered than open. Clinical pharmacology is fully mapped. The rash and Stevens-Johnson liability, while manageable with slow titration in clinical settings, introduces real constraints in certain model systems. Patent expiry is ancient history. The compound does what it does very well, and the bipolar depression angle keeps it genuinely differentiated from lithium and valproate, but that differentiation is now a clinical fact rather than an active research question for most groups.

We score lamotrigine at 52: solidly useful in the right hands, genuinely differentiated on one clinical dimension, backed by strong evidence, but held back by age and thorough characterization. A researcher who specifically needs a state-dependent VGSC blocker or who is working on the bipolar depression mechanism question will find it indispensable. For general prioritization in a research library, it belongs in the catalog as a reference compound rather than a priority target.

Novelty

22

Mechanism promise

35

In-category differentiation

55

Evidence quality

82

Translational signal

78

Research bench value

58

Rationale Lamotrigine earns a mid-range score because the bipolar depression dissociation from the mania-dominant mood stabilizer class is genuinely differentiated and the evidence base is phase-3 strong; novelty and mechanism scores pull it down hard since the compound is fully characterized, decades off-patent, and there is no meaningful frontier science left in the core pharmacology.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Phenyltriazine sodium channel blocker / mood stabilizer

A phenyltriazine voltage-gated sodium channel blocker; uniquely effective for bipolar depression and a first-line maintenance mood stabilizer.

Abstract

Lamotrigine (3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine; CAS 84057-84-1; molecular formula C9H7Cl2N5; molecular weight 256.09) is a phenyltriazine voltage-gated sodium channel blocker developed at Wellcome (now GSK) and approved by the FDA in 1994 under the trade name Lamictal. Mechanism: state-dependent inhibition of voltage-gated sodium channels (preferentially binding inactivated state), reducing release of presynaptic glutamate and aspartate. Secondary inhibition of high-voltage-activated calcium channels and weak antagonism at 5-HT3 receptors contribute to the broader profile. Distinct among anticonvulsants for efficacy in bipolar depression and maintenance mood stabilization (more effective at preventing depressive than manic episodes, opposite the lithium pattern). Plasma half-life is 25 to 33 hours alone, shortened by enzyme-inducing comedications. Hepatic metabolism is primarily glucuronidation. The principal limitation is a benign rash incidence of approximately 10 percent and Stevens-Johnson syndrome at approximately 1 in 1000, both reduced by slow titration over 4 to 6 weeks. Approved for partial-onset seizures, primary generalized tonic-clonic seizures, Lennox-Gastaut syndrome, and bipolar I disorder maintenance. Used as the reference anticonvulsant mood stabilizer and as a clean voltage-gated sodium channel blocker.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-243Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Guanfacine

Plain-language summaryIntrigue 62 / 100

Guanfacine is a more selective cousin of clonidine, originally a blood-pressure drug (Tenex) that found a second life as a non-stimulant ADHD medication (Intuniv, extended-release form). Where clonidine hits all three alpha-2 receptor subtypes broadly, guanfacine prefers the alpha-2A subtype, which is concentrated in the prefrontal cortex (the executive-function part of the brain). Activating it there appears to strengthen working memory and reduce impulsivity, which is the rationale for ADHD use. It is less sedating than clonidine at equivalent effect and is FDA-approved for ADHD in children and adolescents. Often combined with stimulants when stimulants alone are insufficient. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

51/100

Canonical alpha-2A PFC probe with mature ADHD evidence; novelty is low, precision is high

Look, guanfacine is a genuinely useful compound and we’re glad it’s in the library, but let’s be honest about where it sits in the research landscape. This is a 1970s Sandoz molecule, FDA-approved for hypertension in 1986, with the ADHD indication following in 2009 as Intuniv. The core chemistry and pharmacology have been understood for decades, and there’s no mystery left in the primary mechanism.

What keeps it interesting is the alpha-2A subtype selectivity story. Clonidine predates guanfacine and acts across 2A, 2B, and 2C subtypes with less discrimination; guanfacine runs roughly 25-fold selective for 2A over the other subtypes. That matters because alpha-2A receptors dominate the prefrontal cortex, where adrenergic tone directly modulates working memory and executive function through post-synaptic signaling that reduces cAMP and increases the signal-to-noise ratio of PFC pyramidal neurons. Amy Arnsten’s work at Yale is the anchor here, and her group has done the most rigorous mapping of how alpha-2A agonism strengthens PFC network firing without the sedation you get from clonidine at comparable doses.

As a bench tool, guanfacine is the reference compound for alpha-2A pharmacology in the PFC. If you’re running experiments on stress-induced working memory impairment, age-related cognitive decline, or the adrenergic circuitry underlying impulsivity, guanfacine is your cleanest available probe. That’s a real point in its favor, and we score bench utility accordingly.

The evidence base is mature and solid. Multiple phase 3 RCTs in pediatric ADHD, a clean safety profile relative to stimulant alternatives, and well-replicated preclinical work in non-human primates and rodent models going back decades. That said, the effect sizes in ADHD are modest compared to stimulants, and the translational signal, while real and confirmed, doesnt represent a paradigm-defining clinical outcome. It’s a solid, confirmed, specific effect; not a revolutionary one.

We think the honest limitation here is novelty. There’s not much territory left to explore in the core mechanism. New applications do surface, including PTSD (guanfacine for hyperarousal, with some promising small trials out of groups like Pitman’s at Harvard) and emerging work on stress-sensitization in substance use disorders, and those angles give the score a small lift. But for most bench programs that dont specifically need an alpha-2A probe, guanfacine isnt the compound that’s going to define a new research direction. It does a specific job extremely well, and if that job is yours, it belongs in your toolkit.

Novelty

20

Mechanism promise

42

In-category differentiation

58

Evidence quality

73

Translational signal

67

Research bench value

63

Rationale Guanfacine earns on differentiation and evidence as the canonical alpha-2A selective agonist and an FDA-approved compound with replicated ADHD trials, but a 1970s mechanism and fully mapped pharmacology hold novelty and mechanism scores low, producing a mid-tier overall that reflects its value as a precision tool rather than a research frontier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective alpha-2A adrenergic agonist

A selective alpha-2A adrenergic agonist; an antihypertensive repurposed as a non-stimulant ADHD treatment with greater alpha-2A selectivity than clonidine.

Abstract

Guanfacine (N-{[2-(2,6-dichlorophenyl)acetyl]amino}guanidine; CAS 29110-47-2; molecular formula C9H9Cl2N3O; molecular weight 246.10) is a selective alpha-2A adrenergic agonist developed at Sandoz in the 1970s and approved by the FDA in 1986 under the trade name Tenex (immediate release) and 2009 as Intuniv (extended release for ADHD). Distinct from clonidine by greater alpha-2A subtype selectivity (approximately 25-fold over alpha-2B and alpha-2C); the alpha-2A subtype predominates in the prefrontal cortex where it modulates working memory and executive function, supporting the cognitive enhancement seen in ADHD. The CNS-prefrontal cortex effect is more pronounced than the cardiovascular effect at clinical ADHD doses. Plasma half-life is approximately 17 hours, supporting once-daily dosing in the ER formulation. Renal excretion is the principal clearance pathway. Approved for hypertension and (Intuniv) ADHD in children and adolescents. Used as the canonical alpha-2A selective agonist in prefrontal cortex pharmacology and ADHD research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-259Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Enclomiphene

Plain-language summaryIntrigue 62 / 100

Enclomiphene is the pure antagonist isomer of clomiphene, isolated and developed by Repros Therapeutics (as Androxal) for male hypogonadism. By stripping out the estrogenic zuclomiphene component, it offers the testosterone-raising effect of clomiphene without the lingering hot-flash and mood side effects that bother some men on the racemic mixture. Phase 3 trials showed it raised testosterone in obese hypogonadal men while preserving sperm production, a key advantage over standard testosterone replacement. The FDA declined approval in 2016, citing trial design issues, and Repros went bankrupt. It remains popular in men’s-health clinics for fertility-preserving testosterone boosting and as post-cycle therapy. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

53/100

Clean pure ER antagonist with Phase 3 efficacy data; best tool for HPG axis work without the zuclomiphene confound

Look, enclomiphene isn’t exciting the way triple incretins or mitochondrial peptides are exciting. It’s an isomer of a compound that’s been in the fertility pharmacopeia since the 1960s. But here’s what earns its place in the library: standard clomiphene is a mixture of (E) and (Z) isomers, and the (Z) zuclomiphene is a partial estrogen agonist with a plasma half-life of roughly 30 days. That’s a confound you can’t work around in most experimental timelines. Enclomiphene strips it out, leaving a pure ER antagonist with a clean ~30-hour half-life and no estrogenic activity.

The mechanism itself is well-understood, which is why novelty scores low. Hypothalamic ER blockade releases negative feedback on GnRH; pulsatile GnRH drives FSH and LH elevation; elevated gonadotropins stimulate Leydig cell testosterone while FSH sustains Sertoli cell function and active spermatogenesis. That last part is why this isn’t just another SERM: you can restore testosterone toward eugonadal range without bypassing the HPG axis, which means testicular volume and sperm production are preserved. Thats a genuinely useful separation for investigators modeling male secondary hypogonadism, where TRT-driven FSH suppression would otherwise confound the question entirely.

Repros ran real Phase 3 trials. The ZA-304 and ZA-203 programs demonstrated testosterone normalization and improved spermatogenic parameters in obese men with secondary hypogonadism. FDA rejected the NDA twice, in 2015 and 2016, both times citing CMC and clinical pharmacology deficiencies rather than disputing efficacy. Cosette Pharmaceuticals has since licensed the compound and development is ongoing. The translational signal is solid: multiple trials, real effect sizes, demonstrated human replication. What limits the evidence score is single-sponsor origin; the data hasn’t been independently stress-tested across separate lab groups the way a mature approved drug would be.

Bench value comes from specificity, not novelty. If you’re running HPGA axis work and need to clamp hypothalamic ER without estrogenic contamination and without a month-long wait for zuclomiphene clearance, this is the cleaner tool. Tamoxifen carries different receptor selectivity profiles; clomiphene brings the Z-isomer problem straight back; there isnt a functionally equivalent alternative for this specific niche. That differentiation is real even if the underlying biology isnt new. We think the score around 53 reflects that correctly: a well-positioned, genuinely useful research compound that is honest about what it isn’t.

Novelty

38

Mechanism promise

45

In-category differentiation

62

Evidence quality

58

Translational signal

68

Research bench value

50

Rationale Enclomiphene’s differentiation score carries the overall: stripping the estrogenic, long-lived zuclomiphene isomer out of clomiphene produces a pharmacologically cleaner research tool with no real substitute in male HPGA axis work. Novelty and mechanism scores are held down by the fact that ER antagonism at the hypothalamus is well-understood biology from the 1960s; evidence quality is penalized for single-sponsor Phase 3 data that hasn’t been independently replicated across labs.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective estrogen receptor antagonist ((E)-isomer of clomiphene)

The (E)-isomer of clomiphene; a pure ER antagonist without the estrogenic zuclomiphene component, investigated for male hypogonadism.

Abstract

Enclomiphene ((E)-2-[4-(2-chloro-1,2-diphenylvinyl)phenoxy]-N,N-diethylethanamine; CAS 7599-79-3; molecular formula C26H28ClNO; molecular weight 405.96) is the (E)-isomer of clomiphene, a pure ER antagonist developed by Repros Therapeutics for male hypogonadism with the trade name Androxal. The compound antagonizes hypothalamic ER, releasing negative feedback on GnRH; consequent FSH and LH elevation drives endogenous testosterone production by Leydig cells. Distinct from exogenous testosterone replacement, enclomiphene preserves spermatogenesis and testicular volume because the elevated FSH supports continued Sertoli cell function. Phase 3 trials in obese men with secondary hypogonadism demonstrated efficacy in restoring eugonadal testosterone and improving spermatogenic parameters; the FDA declined approval (twice, 2015 and 2016) citing CMC and clinical pharmacology concerns rather than efficacy. The compound has been licensed and is in development at Cosette Pharmaceuticals. Plasma half-life is approximately 30 hours, much shorter than the 30-day zuclomiphene half-life. Used as the canonical pure SERM antagonist for male hypogonadism research and as PCT.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-275Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Insulin (Research)

Our opinion on this compoundResearch workhorse

52/100

Canonical metabolic reference probe with irreplaceable bench utility but near-zero novelty

Look, there is no compound in biology more foundational than insulin. Banting and Best cracked it in 1921. The receptor was cloned, the IRS-1/2 scaffolding was mapped, the PI3K-Akt axis was traced to GLUT4 translocation, and the whole signaling story was essentially complete by the mid-1990s. From a novelty standpoint this scores at the floor. We’re not being harsh; thats just the reality of a 100-year-old Nobel Prize molecule.

What keeps insulin interesting as a research tool is the same thing that keeps it from being a frontier compound: its centrality. If you’re running any experiment touching glucose uptake, anabolic signaling, or metabolic flux, you’re almost certainly using insulin as the reference stimulus or the positive control. There’s no substitute. The IGF-1R cross-talk is relevant for cancer metabolism work, and the PI3K/Akt/mTOR axis that insulin activates sits upstream of half the longevity and senescence biology being done right now. So bench value here is genuinely high. But insulin is the reference, not the question.

Here’s the honest picture for a research team: the evidence quality and translational signal are as strong as they get. This is an approved therapeutic with over a century of replicated human data and a fully characterized, essential mechanism. But thats actually the problem for research prioritization. When something is this well-understood, you’re not learning new biology from the compound itself; you’re using it as a tool to probe other things. That use case is real and important, but it isn’t where the frontier is.

We think insulin occupies a specific, defensible niche: the essential stimulus compound for anyone working on IR biology, GLUT4 trafficking, PI3K-Akt signaling in cancer or longevity contexts, or any assay that needs a defined, clean anabolic signal. For those programs, you can’t replace it. What we don’t think is that insulin should be the primary research target for a forward-looking program, because the interesting biology has moved to receptor analogs, biased agonists, and dual-signaling molecules that do things insulin itself doesn’t do.

One operational note worth flagging: the hypoglycemia risk is acute and serious, and institutional protocols for in vivo insulin work are non-trivial. That doesn’t change the score, but it’s a real consideration for bench setup. Ultimately a low-50s score here is exactly right: genuine irreplaceable utility and unimpeachable evidence pull it up; the complete absence of new mechanism or frontier signal pull it firmly away from the compounds investigators should be prioritizing.

Novelty

12

Mechanism promise

22

In-category differentiation

58

Evidence quality

88

Translational signal

88

Research bench value

75

Rationale Insulin scores at the floor on novelty and mechanism (fully mapped since the mid-1990s, no new biology to find in the compound itself) but its evidence base and translational signal are essentially perfect, and its bench value as the irreplaceable reference standard for IR/PI3K-Akt work keeps it from collapsing. Low-50s overall reflects a foundational workhorse that researchers use to ask questions about other things, not a frontier compound.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Peptide hormone (51-amino-acid disulfide-linked dipeptide)

The pancreatic peptide hormone insulin; the foundational glucose-regulatory hormone and a research probe for metabolic and anabolic biology.

Abstract

Insulin (CAS 9004-10-8; A-chain 21 amino acids, B-chain 30 amino acids; total molecular weight approximately 5808 Da for human insulin) is the pancreatic peptide hormone discovered by Banting and Best in 1921 (Nobel Prize 1923) and synthesized as recombinant human insulin (Humulin) in 1982 by Genentech, the first FDA-approved recombinant pharmaceutical. Pharmacologically, insulin binds the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) with substantially higher affinity for IR. Receptor binding triggers tyrosine kinase activation of IRS-1/2 and downstream PI3K-Akt signaling, regulating glucose uptake (GLUT4 translocation), glycogen synthesis, lipogenesis, and protein synthesis. Modern formulations include rapid-acting analogs (lispro, aspart, glulisine), regular insulin, intermediate (NPH), long-acting (glargine, detemir, degludec), and ultra-long-acting (degludec). Approved indications: type 1 diabetes (essential), type 2 diabetes (when oral agents fail). The principal safety risk is hypoglycemia, severe enough to cause neuronal injury or death; insulin is among the leading drug-related causes of medical emergency department visits. Recreational anabolic use has been documented but is associated with high acute mortality. Used as the canonical metabolic hormone in academic biology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-292Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Nicergoline

Plain-language summaryIntrigue 40 / 100

Nicergoline (Sermion) is a semisynthetic ergoline developed at Farmitalia in Italy and approved across Europe for cerebrovascular disease and age-related cognitive decline. It blocks alpha-1 adrenergic receptors (causing cerebral vessel dilation), inhibits platelet aggregation, and has weak cholinergic effects. Some studies suggested mild improvements in memory and behavior in dementia patients, but the evidence base is heavily Eastern European and methodologically uneven. It is no longer marketed in the US and is rarely used in modern Western practice. Survives in nootropic communities and in markets that approved it long ago. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

35/100

A decades-old European-approved ergoline cerebrovascular agent with genuine but dated multi-target activity and thin modern replication

Nicergoline is a semisynthetic ergoline derivative that’s been on European pharmacy shelves since the 1970s under the name Sermion, indicated for cerebrovascular insufficiency and age-related cognitive decline. That lineage tells you most of what you need to know about where it sits in the 2025 research conversation: it’s a mature compound with a real but dated evidence base, occupying a corner of the literature that doesn’t see a lot of fresh traffic.

The mechanism has some genuine layers worth acknowledging. Alpha-1 adrenergic antagonism in cerebral vasculature is the headline, but nicergoline also inhibits platelet aggregation, shows weak nicotinic and muscarinic activity, and has been reported to modulate acetylcholinesterase activity in several preclinical models. Thats a multi-target profile, and we don’t want to dismiss it entirely. The problem is that none of those mechanisms are novel in the current research climate. Alpha-1 antagonism for cerebrovascular dilation is thoroughly trodden ground; AChE modulation is the mechanism half the cholinergic literature has already exhausted; platelet inhibition is standard for anything touching vascular biology. Stacking them in one molecule is interesting historically but doesn’t create meaningful new pharmacology by today’s standards.

The evidence base is real. European approval means clinical trials were run and regulators signed off, and there are systematic reviews and meta-analyses in the cognitive decline space suggesting modest improvements in neuropsychological outcomes in patients with cerebrovascular disease. But here’s the thing: by modern trial design standards, the pivotal evidence is unimpressive. Many core studies are old, small-N, and built around diagnostic categories like cerebrovascular insufficiency and mild cognitive impairment that have been substantially revised since. Independent replication using current methodology is thin.

Differentiation is the core problem. If you’re working on cerebrovascular biology, there are more specific probes. If you’re targeting alpha-1 adrenergic systems in the CNS, there are cleaner tools. If you’re chasing AChE biology, the cholinesterase inhibitor literature is far richer and more current. Nicergoline doesn’t define its category or dominate on any single dimension. Its value is narrowly as a reference ergoline cerebrovascular agent for investigators building on the specific European literature of that pharmacological class, and that’s a limited research mandate.

We’d prioritize nicergoline only for programs that specifically need a comparator within the ergoline cerebrovascular space or are revisiting historical mechanistic claims with modern methodology. For anyone else, the opportunity cost is high relative to what adjacent mechanistic territory can offer.

Novelty

22

Mechanism promise

35

In-category differentiation

30

Evidence quality

48

Translational signal

45

Research bench value

35

Rationale Nicergoline is a mature, EU-approved compound with a real multi-target mechanism (alpha-1 antagonism, AChE modulation, platelet inhibition), but novelty is negligible by 2025 standards, differentiation against cleaner probes in each mechanistic category is weak, and the clinical evidence base is old and low-powered by modern RCT criteria. Scores land in the piracetam tier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Ergoline derivative / alpha-1 antagonist + cerebrovascular agent

A semisynthetic ergoline derivative; an alpha-1 adrenergic antagonist with cerebrovascular and acetylcholinesterase modulatory activity.

Abstract

Nicergoline (10-alpha-methoxy-1,6-dimethylergoline-8-beta-methanol 5-bromonicotinate; CAS 27848-84-6; molecular formula C24H26BrN3O3; molecular weight 484.39) is a semisynthetic ergoline developed at Farmitalia (Italy) and approved in several European countries under the trade name Sermion for cerebrovascular disease and age-related cognitive decline. Mechanism: alpha-1 adrenergic antagonism (cerebrovascular dilation), inhibition of platelet aggregation, weak nicotinic and muscarinic effects, and modulation of acetylcholinesterase activity in some studies. Plasma half-life is approximately 2 hours for the parent compound; the active metabolite 1,6-dimethyl-8-beta-hydroxymethyl-10-alpha-methoxy-ergoline (MMDL) has substantially longer half-life. Approved for cerebrovascular insufficiency in Europe; not approved in the US. Used as a reference ergoline cerebrovascular agent in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-308Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
D-Serine

Plain-language summaryIntrigue 68 / 100

D-serine is the mirror-image form of the amino acid serine, and your brain makes it on purpose. It is the obligate co-agonist at the synaptic NMDA receptor, meaning the receptor will not open without it sitting in a dedicated pocket alongside glutamate. An enzyme called serine racemase builds it; another called DAAO breaks it down. Researchers have tested giving it as a drug to boost NMDA function in schizophrenia (where reduced NMDA signaling is implicated in negative and cognitive symptoms) and in depression. Phase 2 trials show small but real effects. The competing strategy is to inhibit DAAO so the brain keeps more of its own. The canonical NMDA glycine-site co-agonist for neuroscience research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

48/100

Canonical endogenous NMDA co-agonist; indispensable synaptic probe with modest clinical signal in schizophrenia

Yeah, D-serine isn’t a discovery compound or a clinical moonshot. It’s the obligatory co-agonist at synaptic NMDA receptors that your brain makes itself, and has been studied intensively since the late 1990s when Wolosker, Snyder and colleagues pinned serine racemase as the biosynthetic enzyme. On novelty, we’re not pretending this is fresh territory.

Here’s the thing: what makes D-serine interesting in 2026 isn’t novelty, it’s bench utility. If you’re running any NMDA receptor biology — LTP assays, synaptic plasticity models, glutamate hypothesis schizophrenia work — D-serine is the compound you reach for to saturate the glycine site at synaptic NMDARs. And that matters because D-serine and glycine are not interchangeable here: D-serine is the preferred endogenous co-agonist at synaptic NMDARs in cortex and hippocampus, while glycine hits extrasynaptic receptors preferentially. Use glycine where you should use D-serine, and you’re probing a different receptor population. That distinction is load-bearing in any serious NMDA-focused program.

The mechanism is genuinely elegant. Serine racemase converts L-serine to D-serine; D-amino acid oxidase (DAAO) degrades it. That serine racemase/DAAO regulatory axis is itself a research target — DAAO inhibitors like sodium benzoate and luvadaxistat (TAK-831) were developed precisely because they elevate endogenous D-serine levels without flooding the system with exogenous amino acid. The endogenous level story powers the schizophrenia hypothesis: reduced NMDA receptor function from insufficient D-serine availability is one of the more coherent mechanistic accounts of negative symptoms and cognitive deficits in that population.

On clinical evidence, the phase 2 trials exist. Heresco-Levy’s group and several others have run them. Effects on negative symptoms and cognitive function are real but modest — consistent direction, meaningful p-values in several trials, but not effect sizes that would get anyone excited at a clinical development meeting. It hasnt gone to phase 3. The DAAO inhibitor path is the more active clinical development vector right now, which makes exogenous D-serine administration somewhat less central as a therapeutic candidate and somewhat more of a reference tool.

What we like is the bench probe value. Any lab interrogating NMDA co-agonism, glycine-site pharmacology, or the serine racemase/DAAO axis needs D-serine in the toolkit. Sourcing is clean — high-purity free amino acid from major chemical suppliers, straightforward aqueous reconstitution, no solubility headaches. What we dont love is the clinical stall. A compound this tightly coupled to NMDA synaptic biology should anchor research programs, and it does — just not as a frontier target. It anchors them as the reference standard against which everything more novel gets measured.

Novelty

28

Mechanism promise

55

In-category differentiation

55

Evidence quality

52

Translational signal

42

Research bench value

65

Rationale D-serine’s D-stereoisomeric identity and specific serine racemase/DAAO biosynthetic axis distinguish it from generic L-serine or plain amino acids, so the basic-aa cap does not apply; scores are dragged down by low novelty (mature 1990s-2000s literature) and a stalled clinical development arc, but bench-value is meaningfully elevated as the canonical synaptic NMDA co-agonist that cannot simply be substituted with glycine in properly-designed NMDAR studies.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous NMDA receptor co-agonist

D-stereoisomer of serine; an endogenous obligatory co-agonist at the NMDA receptor glycine site.

Abstract

D-serine ((R)-2-amino-3-hydroxypropanoic acid; CAS 312-84-5; molecular formula C3H7NO3; molecular weight 105.09) is the D-stereoisomer of serine, an endogenous obligatory co-agonist at the glycine site of NMDA receptors. The compound is biosynthesized in the brain by serine racemase (the enzyme that converts L-serine to D-serine) and is metabolized by D-amino acid oxidase (DAAO). D-serine is the principal endogenous co-agonist for synaptic NMDA receptors in the cortex and hippocampus, while glycine itself co-agonizes extrasynaptic NMDA receptors. Pharmacologically, exogenous D-serine elevates NMDA receptor function, with research interest in schizophrenia (where reduced NMDA function is hypothesized as a contributor to negative symptoms and cognitive deficits) and depression (NMDA modulation as antidepressant target). Phase 2 trials in schizophrenia have shown small effects. Plasma half-life is approximately 4 hours; oral bioavailability is moderate. The DAAO inhibitor approach is an alternative to direct D-serine administration. Used as the canonical NMDA glycine-site co-agonist in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-374Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Stanozolol

Plain-language summaryIntrigue 48 / 100

Stanozolol (Winstrol) is a 17-alpha-alkylated synthetic anabolic steroid developed by Sterling-Winthrop in 1962, distinguished by a pyrazole ring fused to the steroid A-ring. The fusion shifts the anabolic-to-androgenic ratio higher than testosterone and supports oral activity. FDA-approved historically for hereditary angioedema (largely replaced now by C1-inhibitor and icatibant) and a few other niche uses. Its place in popular memory belongs to Ben Johnson, whose 1988 Seoul Olympic 100m gold medal was stripped after a positive stanozolol test. Hepatotoxicity is the main limiting concern, the standard cost of 17-alpha-alkylation. Schedule III. Used in research as a reference oral AAS. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

37/100

A historically significant reference AAS with mature mechanism and declining research relevance

Look, stanozolol is not a mystery. It’s been around since 1962, it made Ben Johnson the most famous disqualified sprinter in history, and the mechanism is what you’d expect: androgen receptor agonism via a pyrazol-fused 17-alpha-alkylated backbone that shifts the anabolic-to-androgenic ratio favorably relative to testosterone. Sterling-Winthrop knew what they were doing structurally. But knowing what something does and finding it interesting in 2026 are different things.

The mechanism story starts and ends with AR binding. The pyrazole fusion at the A-ring is chemically clever for its era, and the oral bioavailability is real. What isn’t real anymore is the clinical urgency. The hereditary angioedema indication that got Winstrol its FDA approval has been largely displaced by C1-inhibitor concentrates and icatibant. Those agents are cleaner, better-tolerated, and don’t carry the hepatotoxicity liability that 17-alpha-alkylated steroids all share to varying degrees. The indication that justified the compound’s existence in the clinic is essentially a historical artifact at this point.

What we’re left with is a Schedule III reference compound. That’s not nothing. If you’re running AAS pharmacology studies, SHBG displacement work, or comparative androgen receptor affinity panels, stanozolol occupies a specific and well-characterized position in the reference set. The literature is extensive enough that you can contextualize your findings against a real body of evidence. That’s the bench value argument, and it’s legitimate but limited. Newer AAS analogs with more interesting selectivity profiles have appeared in the literature if your goal is genuinely advancing the mechanistic frontier.

The evidence quality is actually respectable for what it is. FDA approval, multi-decade use, clear pharmacokinetics, well-characterized toxicity. But high evidence quality on a mature well-understood compound is almost a negative signal for research interest. It means the question has already been answered. There’s no ambiguity left to resolve with stanozolol that hasn’t already been resolved, which is why the novelty score sits at the floor and drags the overall down hard.

Honestly, if you’re building a research program around androgen biology in 2026, the interesting questions are in selective androgen receptor modulators, tissue-selective AAS fragments, or non-steroidal AR modulators. Stanozolol tells you where that field came from, not where it’s going. We think it earns its place in the library as a reference compound, but we’d be doing investigators a disservice if we scored it as if it were an active frontier.

Novelty

18

Mechanism promise

22

In-category differentiation

35

Evidence quality

60

Translational signal

55

Research bench value

48

Rationale Stanozolol scores low on novelty and mechanism because it’s a 1962 oral AAS with well-understood AR agonism and an indication space that modern therapy has largely superseded; evidence quality and translational signal are genuine given FDA approval and decades of clinical use, but those points are offset by near-zero novelty and limited differentiation from a saturated class. Schedule III cap (75) does not bind; the raw weighted score of 37 reflects the compound’s historical-reference-only status.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

17-alpha-alkylated heterocyclic AAS

A pyrazol-fused 17-alpha-alkylated AAS; the steroid involved in the Ben Johnson 1988 Olympic doping case; clinically used historically for hereditary angioedema.

Abstract

Stanozolol (17-beta-hydroxy-17-alpha-methyl-5-alpha-androstano[3,2-c]pyrazole; CAS 10418-03-8; molecular formula C21H32N2O; molecular weight 328.49) is a pyrazol-fused 17-alpha-alkylated synthetic AAS developed by Sterling-Winthrop in 1962 and approved by the FDA (Winstrol) for hereditary angioedema and other indications. The pyrazole fusion at the A-ring increases the anabolic-to-androgenic ratio relative to testosterone and supports oral activity. Plasma half-life is approximately 9 hours (oral). Schedule III. The compound’s place in popular culture is dominated by the Ben Johnson case at the 1988 Seoul Olympics, where his 100m gold medal was stripped after positive testing for stanozolol. The clinical use in hereditary angioedema (rare, often replaced by C1-INH or icatibant in modern practice) demonstrates the compound’s effect on hepatic protein synthesis. Hepatotoxicity is the principal limitation. Used as a reference oral AAS in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-390Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Tacrine

Plain-language summaryIntrigue 48 / 100

Tacrine, sold as Cognex, was the first FDA-approved Alzheimer disease medication (1993). It is rarely prescribed today owing to hepatotoxicity, but remains a research reference compound for cholinesterase inhibition. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

31/100

Historically foundational AChE inhibitor, clinically obsolete, retained only as a pharmacological probe and hybrid-molecule scaffold

Look, tacrine holds a specific place in pharmacological history. It was the compound that proved cholinesterase inhibition could work in Alzheimer disease. That was 1993. The question in 2026 is what it offers a researcher today, and the honest answer is: narrow but real probe utility, not much else.

The mechanism story is more interesting than people give it credit for. Tacrine isn’t a clean AChE inhibitor the way donepezil is; the aminoacridine scaffold also hits BChE and picks up weak NMDA receptor antagonism and modest sodium channel blockade. For researchers studying multi-target directed ligands (MTDL) in the AD space, that profile matters. Tacrine hybrids with memantine, with galantamine, with various natural product fragments have been a minor but productive research thread going back to the early 2000s. The scaffold is a legitimate template for MTDL design, and thats where we think the contemporary bench value actually lives.

What we don’t like is everything else about it as a primary research target. The hepatotoxicity is dose-related and reversible on discontinuation in most cases, yes, but it means roughly half of patients in the original trials developed clinically significant ALT elevation requiring monitoring or drug discontinuation. That’s not a side-effect profile anyone is trying to rehabilitate for clinical use when donepezil, rivastigmine, and galantamine all exist. The translational signal, real and FDA-validated, is essentially historical now. Nobody is running a new tacrine arm in a clinical study in 2026.

Evidence quality is genuinely solid in one narrow sense: this compound cleared FDA approval with multiple phase 3 trials, establishing a regulatory and clinical record that most research compounds never approach. But the evidence is old, effect sizes were modest by modern standards, and the safety signal ultimately drove market withdrawal in 2013 after declining prescriptions made the compound commercially unviable. We score evidence at 65 here, crediting the actual clinical program, not the contemporary relevance of the data.

Novelty is essentially zero. The mechanism is mature, the compound is decades old, the literature is not growing in any meaningful direction. Differentiation gets punished hard because better-tolerated AChE inhibitors have replaced tacrine everywhere that matters, except in enzyme kinetics assays and hybrid-molecule research where it functions as a reference standard.

Honestly, if your research program is in cholinesterase pharmacology or MTDL design for neurodegeneration, tacrine is a legitimate template and a useful comparator. That’s real. But it’s not a compound a serious investigator would prioritize as a primary target right now, and scoring it higher than that would misrepresent what the library is for.

Novelty

10

Mechanism promise

22

In-category differentiation

18

Evidence quality

65

Translational signal

40

Research bench value

52

Rationale Tacrine’s score is dragged down by near-zero novelty and clear clinical obsolescence driven by hepatotoxicity; surviving research value is narrow, living in its role as a reference compound and MTDL scaffold rather than as a therapeutic lead worth pursuing.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Aminoacridine acetylcholinesterase inhibitor

The first FDA-approved Alzheimer disease therapy (1993), withdrawn for hepatotoxicity but historically important and retained as a research probe.

Abstract

Tacrine (Cognex, 1,2,3,4-tetrahydroacridin-9-amine; CAS 321-64-2; molecular formula C13H14N2; molecular weight 198.27) is the first FDA-approved cholinesterase inhibitor for Alzheimer disease, granted approval in 1993 and subsequently withdrawn from the US market in 2013 due to hepatotoxicity (approximately 50 percent of patients developed clinically significant ALT elevation requiring monitoring or discontinuation). The compound is a non-selective reversible AChE and BChE inhibitor based on an aminoacridine scaffold. Mechanism includes additional weak NMDA receptor antagonism and modest sodium channel blockade, distinguishing the pharmacology from the more selective subsequent AChE inhibitors. The historical significance of tacrine is substantial; the compound established cholinesterase inhibition as a viable therapeutic strategy for Alzheimer disease and led to development of the more tolerable second-generation agents. The compound retains research utility as a pharmacological probe and AChE reference compound. Pharmacokinetics: short half-life (3 to 4 hours), four-times-daily dosing required in the marketed formulation. Hepatotoxicity is dose-related and reversible on discontinuation in most cases.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-048Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Tirzepatide

Plain-language summaryIntrigue 93 / 100

Tirzepatide, sold as Mounjaro and Zepbound, is the first dual GLP-1 and GIP receptor agonist. By activating both incretin receptors, it produces more weight loss than semaglutide in head-to-head trials. Approved by the FDA in 2022. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel frontier

80/100

Dual incretins done right: the FDA-approved benchmark that defines what GIP/GLP-1 co-agonism can achieve

Look, tirzepatide isn’t just another incretin. The whole story starts at the receptor pharmacology: GIP and GLP-1 agonism together produce a genuinely additive effect that neither receptor achieves alone. GIP engagement modulates adipose tissue metabolism and potentiates insulin secretion in a glucose-dependent fashion; GLP-1 handles central satiety signaling, gastric emptying delay, and glucagon suppression. Running both pathways simultaneously turns out to be more than the sum of its parts, and the SURMOUNT program is the evidence base that confirmed it at scale.

SURMOUNT-1, published in the New England Journal of Medicine in 2022, showed average weight loss of 20.9% at the 15 mg weekly dose in adults with obesity over 72 weeks, with N above 2500. These arent modest numbers from a single lab. SURMOUNT-2, -3, and -4 extended the findings to T2DM populations, confirmed durability after withdrawal, and locked in the dose-response relationship. Multiple RCTs, multiple populations, consistent signal. The evidence quality here is genuinely high for a peptide compound.

What we find most interesting from a research standpoint is what the GIP component actually contributes. GLP-1 monotherapy was already well-validated before tirzepatide arrived. In a real sense, tirzepatide is the controlled experiment for what layering GIP receptor agonism adds on top of established GLP-1 biology. The GIP receptor’s role in adipose tissue, its interactions with adiponectin signaling, and the downstream effects on fat mass independent of energy intake are not fully characterized, and tirzepatide is one of the few available probes for studying that biology at clinically meaningful concentrations.

We dont think it’s breaking news anymore, though. Tirzepatide is FDA-approved, widely prescribed, and the research program is maturing fast. Novelty has a shelf life, and this compound is burning through it. Retatrutide is already in phase 2 with a triple agonist profile adding glucagon receptor activity, which makes tirzepatide look like a stepping stone in a rapidly evolving pharmacology story. Bench investigators focused purely on incretin frontier biology will want to be watching that space closely.

For investigators working on metabolic pharmacology, incretin receptor biology, adipose tissue signaling, or GLP-related satiety circuitry, tirzepatide remains one of the most useful tools available. The evidence base is unusually clean. The mechanism is well-defined. And the gap it opened between dual and single GLP-1 agonism is exactly the kind of differentiated signal that gives a research program somewhere real to go. The score reflects a compound that genuinely moved the field, even as the field is already starting to move past it.

Novelty

72

Mechanism promise

85

In-category differentiation

80

Evidence quality

87

Translational signal

88

Research bench value

68

Rationale Tirzepatide scores high on mechanism promise and evidence quality because the SURMOUNT trial program is unusually clean and large for a peptide this young, and the dual-receptor pharmacology is genuinely differentiated from GLP-1 monotherapy. Novelty is real but moderating now that it’s an approved, widely-prescribed agent; retatrutide’s emergence makes tirzepatide look increasingly like the floor of what’s possible in this class rather than the ceiling.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

GIP/GLP-1 dual receptor agonist

A dual GIP and GLP-1 receptor agonist FDA-approved as Mounjaro (T2DM, 2022) and Zepbound (obesity, 2023), producing greater weight loss than GLP-1-only agents.

Abstract

Tirzepatide (Mounjaro, Zepbound; CAS 2023788-19-2; molecular weight 4813.54) is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor co-agonist developed by Eli Lilly and approved by the FDA for type 2 diabetes (2022) and chronic weight management (2023). The compound is a 39-amino-acid synthetic peptide based on the GIP scaffold with modifications at positions enabling GLP-1 receptor agonism alongside GIP receptor activity. Mechanism is dual GIP/GLP-1 receptor agonism producing complementary effects: GIP engagement adds to GLP-1’s glucose-dependent insulin secretion and contributes to weight regulation through fat metabolism modulation; GLP-1 contributes the central satiety, gastric emptying, and glucagon suppression effects. The combination produces substantially greater weight loss than GLP-1 monotherapy: SURMOUNT trials showed 15 to 22 percent weight loss over 72 weeks at 5 to 15 mg weekly doses. Approved doses titrate to 5, 10, or 15 mg per week subcutaneous.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-083Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 63 64 65 66 67 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.